ibudilast has been researched along with Multiple Sclerosis in 10 studies
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Ibudilast showed significant treatment effect on brain atrophy and magnetization transfer ratio (MTR) of normal-appearing brain tissue but not in new/enlarging T2 lesion in the SPRINT-MS randomized clinical trial." | 9.69 | Effect of ibudilast on thalamic magnetization transfer ratio and volume in progressive multiple sclerosis. ( Cohen, JA; Fox, RJ; Mahajan, KR; Nakamura, K; Ontaneda, D; Zheng, Y, 2023) |
| "To investigate the treatment effect of ibudilast on thalamic atrophy more than 96 weeks in the phase 2 trial in progressive(MS Secondary and Primary Progressive Ibudilast NeuroNEXT Trial in Multiple Sclerosis [SPRINT-MS])." | 9.69 | The effect of ibudilast on thalamic volume in progressive multiple sclerosis. ( Bien, H; Brewer, K; Eloyan, A; Klawiter, EC; Nicholson, S; Russo, AW; Tobyne, SM, 2023) |
| "Ibudilast treatment was not associated with a change in either serum or CSF NfL." | 7.01 | Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis. ( Barro, C; Bermel, RA; Chase, M; Coffey, CS; Fox, RJ; Goodman, AD; Karafa, M; Klawiter, EC; Konig, V; Kuhle, J; Naismith, RT; Raska, P, 2021) |
| "Ibudilast is a nonselective phosphodiesterase inhibitor which works by blocking the cleavage of cyclic adenosine monophosphate (cAMP)." | 6.53 | Ibudilast for the treatment of multiple sclerosis. ( Goodman, AD; Gyang, T; Smith, AD, 2016) |
| "Ibudilast is a phosphodiesterase inhibitor, effective on the function of glial cells and lymphocytes, and inhibits the release of TNF-α by inflammatory cells." | 5.91 | Nose to brain delivery of ibudilast micelles for treatment of multiple sclerosis in an experimental autoimmune encephalomyelitis animal model. ( Aliomrani, M; Kazemi, M; Sharifian, A; Varshosaz, J, 2023) |
| " Ibudilast showed significant treatment effect on brain atrophy and magnetization transfer ratio (MTR) of normal-appearing brain tissue but not in new/enlarging T2 lesion in the SPRINT-MS randomized clinical trial." | 5.69 | Effect of ibudilast on thalamic magnetization transfer ratio and volume in progressive multiple sclerosis. ( Cohen, JA; Fox, RJ; Mahajan, KR; Nakamura, K; Ontaneda, D; Zheng, Y, 2023) |
| "To investigate the treatment effect of ibudilast on thalamic atrophy more than 96 weeks in the phase 2 trial in progressive(MS Secondary and Primary Progressive Ibudilast NeuroNEXT Trial in Multiple Sclerosis [SPRINT-MS])." | 5.69 | The effect of ibudilast on thalamic volume in progressive multiple sclerosis. ( Bien, H; Brewer, K; Eloyan, A; Klawiter, EC; Nicholson, S; Russo, AW; Tobyne, SM, 2023) |
| "To determine whether ibudilast has an effect on brain volume and new lesions in progressive forms of multiple sclerosis (MS)." | 5.41 | Effects of Ibudilast on MRI Measures in the Phase 2 SPRINT-MS Study. ( Bermel, RA; Coffey, CS; Fedler, J; Fox, RJ; Goebel, C; Goodman, AD; Kearney, M; Klawiter, EC; Klingner, E; Naismith, RT; Nakamura, K; Narayanan, S; Yankey, J, 2021) |
| "Ibudilast treatment was not associated with a change in either serum or CSF NfL." | 3.01 | Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis. ( Barro, C; Bermel, RA; Chase, M; Coffey, CS; Fox, RJ; Goodman, AD; Karafa, M; Klawiter, EC; Konig, V; Kuhle, J; Naismith, RT; Raska, P, 2021) |
| "Ibudilast is a nonselective phosphodiesterase inhibitor which works by blocking the cleavage of cyclic adenosine monophosphate (cAMP)." | 2.53 | Ibudilast for the treatment of multiple sclerosis. ( Goodman, AD; Gyang, T; Smith, AD, 2016) |
| "Ibudilast is a phosphodiesterase inhibitor, effective on the function of glial cells and lymphocytes, and inhibits the release of TNF-α by inflammatory cells." | 1.91 | Nose to brain delivery of ibudilast micelles for treatment of multiple sclerosis in an experimental autoimmune encephalomyelitis animal model. ( Aliomrani, M; Kazemi, M; Sharifian, A; Varshosaz, J, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 6 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sharifian, A | 1 |
| Varshosaz, J | 1 |
| Aliomrani, M | 1 |
| Kazemi, M | 1 |
| Nakamura, K | 2 |
| Zheng, Y | 1 |
| Mahajan, KR | 1 |
| Cohen, JA | 1 |
| Fox, RJ | 4 |
| Ontaneda, D | 1 |
| Nicholson, S | 1 |
| Russo, AW | 1 |
| Brewer, K | 1 |
| Bien, H | 1 |
| Tobyne, SM | 1 |
| Eloyan, A | 1 |
| Klawiter, EC | 3 |
| Sormani, MP | 1 |
| Tur, C | 1 |
| Barkhof, F | 1 |
| Naismith, RT | 2 |
| Bermel, RA | 2 |
| Coffey, CS | 2 |
| Goodman, AD | 3 |
| Fedler, J | 1 |
| Kearney, M | 1 |
| Narayanan, S | 1 |
| Goebel, C | 1 |
| Yankey, J | 1 |
| Klingner, E | 1 |
| Raska, P | 1 |
| Barro, C | 1 |
| Karafa, M | 1 |
| Konig, V | 1 |
| Chase, M | 1 |
| Kuhle, J | 1 |
| Maillart, E | 1 |
| Gyang, T | 1 |
| Smith, AD | 1 |
| Fujimoto, T | 1 |
| Sakoda, S | 1 |
| Fujimura, H | 1 |
| Yanagihara, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Regeneration in Cervical Degenerative Myelopathy - a Multi-centre, Double-blind, Randomised, Placebo Controlled Trial Assessing the Efficacy of Ibudilast as an Adjuvant Treatment to Decompressive Surgery for Degenerative Cervical Myelopathy[NCT04631471] | Phase 3 | 400 participants (Anticipated) | Interventional | 2021-12-22 | Recruiting | ||
| A Multi-Center, Open-Label Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS)[NCT02714036] | Phase 1/Phase 2 | 35 participants (Actual) | Interventional | 2016-05-06 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for ibudilast and Multiple Sclerosis
| Article | Year |
|---|---|
Treatment of progressive multiple sclerosis: Challenges and promising perspectives.
Topics: Anti-Inflammatory Agents; Disease Progression; Humans; Multiple Sclerosis; Neurology; Pyridines | 2018 |
Ibudilast for the treatment of multiple sclerosis.
Topics: Animals; Anti-Inflammatory Agents; Brain; Disease Progression; Humans; Multiple Sclerosis; Neuroprot | 2016 |
4 trials available for ibudilast and Multiple Sclerosis
| Article | Year |
|---|---|
Effect of ibudilast on thalamic magnetization transfer ratio and volume in progressive multiple sclerosis.
Topics: Atrophy; Brain; Humans; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Chronic | 2023 |
The effect of ibudilast on thalamic volume in progressive multiple sclerosis.
Topics: Atrophy; Bayes Theorem; Humans; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive | 2023 |
Effects of Ibudilast on MRI Measures in the Phase 2 SPRINT-MS Study.
Topics: Aged; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Phosphodies | 2021 |
Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis.
Topics: Biomarkers; Humans; Intermediate Filaments; Multiple Sclerosis; Multiple Sclerosis, Chronic Progress | 2021 |
4 other studies available for ibudilast and Multiple Sclerosis
| Article | Year |
|---|---|
Nose to brain delivery of ibudilast micelles for treatment of multiple sclerosis in an experimental autoimmune encephalomyelitis animal model.
Topics: Animals; Brain; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Mice; Mice, Inb | 2023 |
Ibudilast: A Paradigm Shift for Progressive Multiple Sclerosis?
Topics: Humans; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Pyr | 2021 |
Primary neuroprotection: the Holy Grail of multiple sclerosis therapy.
Topics: Brain; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Humans; Multiple Sclero | 2010 |
Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats.
Topics: Administration, Oral; Animals; Cell Division; Disease Models, Animal; Encephalomyelitis, Autoimmune, | 1999 |